The HIV Drugs Market is predicted to reach US$ by 2030 from US$ 30.89 billion in 2021, and to grow at a CAGR of 6.2% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Drug Class (Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Integrase Inhibitors, and Combination Drugs), by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Mylan N.V., AbbVie Inc., Bristol-Myers Squibb Company, ViiV Healthcare Limited, Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, and Janssen Pharmaceuticals, Inc. among others
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL HIV Drugs - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL HIV Drugs - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL HIV Drugs - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL HIV Drugs - ANALYSIS & FORECAST, BY REGION
North America HIV Drugs
1. North America HIV Drugs , by Country
1. US
2. Canada
1. North America HIV Drugs , by Product
2. North America HIV Drugs , by Type
3. North America HIV Drugs , by Gender
4. North America HIV Drugs , by Sales Channel
3. Europe HIV Drugs
1. Europe HIV Drugs , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe HIV Drugs , by Product
3. Europe HIV Drugs , by Type
4. Europe HIV Drugs , by Gender
5. Europe HIV Drugs , by Sales Channel
4. Asia Pacific HIV Drugs
1. Asia Pacific HIV Drugs , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific HIV Drugs , by product
3. Asia Pacific HIV Drugs , by Type
4. Asia Pacific HIV Drugs , by Gender
5. Asia Pacific HIV Drugs , by Sales Channel
5. Rest of the World HIV Drugs
1. Rest of the World HIV Drugs , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World HIV Drugs , by Product
3. Rest of the World HIV Drugs , by Type
4. Rest of the World HIV Drugs , by Gender
5. Rest of the World HIV Drugs , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 67
The Antimetabolite Drugs Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/...
The GLP-1 Peptide Drugs Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/p...
Executive Summary
Azoth Analytics has released a research report titled "Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition)" which provides a complete analysis of the Global IgG Mediated Autoimmune Diseases Biologic Drugs industry in terms of market segmentatio...
Executive Summary
Azoth Analytics has released a research report titled "Global Antibiotic Drugs Market (2024 Edition)" which provides a complete analysis of the global Antibiotic Drugs industry in terms of market segmentation By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoro...
Overview of the Global Sex Hormone Drugs Market:
The report discusses everything a marketer requires before investing in the global Sex Hormone Drugs Market during the forecast period 2023-2030. It provides detailed...
Executive Summary
Azoth Analytics has released a research report titled "Incretin Based Drugs Market (2023 Edition)" which provides a complete analysis of the global Incretin Based Drugs industry in terms of market segmentation By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Di...
Overview of the Global Microecological Drugs Market :
The report discusses everything a marketer requires before investing in the global Microecological Drugs Market during the forecast period 2023-2030. It provide...
Overview of the Global Biosynthesis Peptide Drugs Market:
The report discusses everything a marketer requires before investing in the global Biosynthesis Peptide Drugs Market during the forecast period 2023-2030. It...
Overview of the Global Chemical Synthesis Peptide Drugs Market:
The report discusses everything a marketer requires before investing in the global Chemical Synthesis Peptide Drugs Market during the forecast period 2...
Description
The global veterinary dermatology drugs market exhibits positive growth prospects, forecast to expand at a CAGR of 5.4% between 2023 and 2029 to reach USD 8.08 billion in value. Veterinary dermatology focuses on treating skin diseases and disorders in animal patients, covering both...